A N Phillips

Summary

Affiliation: University College London
Country: UK

Publications

  1. ncbi HIV viral load response to antiretroviral therapy according to the baseline CD4 cell count and viral load
    A N Phillips
    Department of Primary Care and Population Sciences, Royal Free and University College Medical School, Rowland Hill Street, London NW3 2PF, England
    JAMA 286:2560-7. 2001
  2. ncbi Theoretical rationale for the use of sequential single-drug antiretroviral therapy for treatment of HIV infection
    Andrew N Phillips
    Royal Free Centre for HIV Medicine and Department of Primary Care and Population Sciences, Royal Free and University College Medical School, Rowland Hill Street, London NW3 2PF, UK
    AIDS 17:1009-16. 2003
  3. ncbi Short-term risk of AIDS according to current CD4 cell count and viral load in antiretroviral drug-naive individuals and those treated in the monotherapy era
    A Phillips
    Royal Free Centre for HIV Medicine, Royal Free and University College Medical School, London, UK
    AIDS 18:51-8. 2004
  4. ncbi Interruption of antiretroviral therapy and risk of cardiovascular disease in persons with HIV-1 infection: exploratory analyses from the SMART trial
    Andrew N Phillips
    Department of Primary Care and Population Sciences, Royal Free University College Medical School, London, UK
    Antivir Ther 13:177-87. 2008
  5. ncbi Outcomes from monitoring of patients on antiretroviral therapy in resource-limited settings with viral load, CD4 cell count, or clinical observation alone: a computer simulation model
    Andrew N Phillips
    HIV Epidemiology and Biostatistics Group, Department of Primary Care and Population Sciences, and Royal Free Centre for HIV Medicine, Royal Free and University College Medical School, University College London, London, UK
    Lancet 371:1443-51. 2008
  6. ncbi Viral load outcome of non-nucleoside reverse transcriptase inhibitor regimens for 2203 mainly antiretroviral-experienced patients
    A N Phillips
    Royal Free Centre for HIV Medicine and Department of Primary Care and Population Sciences, Royal Free and University College, London, UK
    AIDS 15:2385-95. 2001
  7. ncbi Risk of extensive virological failure to the three original antiretroviral drug classes over long-term follow-up from the start of therapy in patients with HIV infection: an observational cohort study
    Andrew N Phillips
    Department of Primary Care and Population Sciences, Royal Free and University College Medical School, London, UK
    Lancet 370:1923-8. 2007
  8. ncbi HIV in the UK 1980-2006: reconstruction using a model of HIV infection and the effect of antiretroviral therapy
    A N Phillips
    Department of Primary Care and Population Sciences, Royal Free Medical School, London, UK
    HIV Med 8:536-46. 2007
  9. ncbi Rate of AIDS diseases or death in HIV-infected antiretroviral therapy-naive individuals with high CD4 cell count
    Andrew N Phillips
    Department of Primary Care and Population Sciences, Royal Free and University College Medical School, London, UK
    AIDS 21:1717-21. 2007
  10. ncbi Human immunodeficiency virus rebound after suppression to <400 copies/mL during initial highly active antiretroviral therapy regimens, according to prior nucleoside experience and duration of suppression
    Andrew N Phillips
    Royal Free Centre for HIV Medicine, Royal Free and University College Medical School, Rowland Hill Street, London NW3 2PF, United Kingdom
    J Infect Dis 186:1086-91. 2002

Detail Information

Publications123 found, 100 shown here

  1. ncbi HIV viral load response to antiretroviral therapy according to the baseline CD4 cell count and viral load
    A N Phillips
    Department of Primary Care and Population Sciences, Royal Free and University College Medical School, Rowland Hill Street, London NW3 2PF, England
    JAMA 286:2560-7. 2001
    ..It is unclear whether delay in initiation of antiretroviral therapy (ART) may lead to a poorer viral load response for patients with human immunodeficiency virus (HIV)...
  2. ncbi Theoretical rationale for the use of sequential single-drug antiretroviral therapy for treatment of HIV infection
    Andrew N Phillips
    Royal Free Centre for HIV Medicine and Department of Primary Care and Population Sciences, Royal Free and University College Medical School, Rowland Hill Street, London NW3 2PF, UK
    AIDS 17:1009-16. 2003
    ..We aimed to explore the use of sequential monotherapy regimens using a mathematical model of quasi-species dynamics, to see if these could take advantage of the poor replicative capacity of highly resistant virus...
  3. ncbi Short-term risk of AIDS according to current CD4 cell count and viral load in antiretroviral drug-naive individuals and those treated in the monotherapy era
    A Phillips
    Royal Free Centre for HIV Medicine, Royal Free and University College Medical School, London, UK
    AIDS 18:51-8. 2004
    ..e., pre-September 1995), especially in those with CD4 cell count > 200 x 10 cells/l, is lacking...
  4. ncbi Interruption of antiretroviral therapy and risk of cardiovascular disease in persons with HIV-1 infection: exploratory analyses from the SMART trial
    Andrew N Phillips
    Department of Primary Care and Population Sciences, Royal Free University College Medical School, London, UK
    Antivir Ther 13:177-87. 2008
    ..Exploratory analyses were performed to better understand the reasons for this observation...
  5. ncbi Outcomes from monitoring of patients on antiretroviral therapy in resource-limited settings with viral load, CD4 cell count, or clinical observation alone: a computer simulation model
    Andrew N Phillips
    HIV Epidemiology and Biostatistics Group, Department of Primary Care and Population Sciences, and Royal Free Centre for HIV Medicine, Royal Free and University College Medical School, University College London, London, UK
    Lancet 371:1443-51. 2008
    ..Our aim was to study the potential consequences of such monitoring strategies, especially in terms of survival and resistance development...
  6. ncbi Viral load outcome of non-nucleoside reverse transcriptase inhibitor regimens for 2203 mainly antiretroviral-experienced patients
    A N Phillips
    Royal Free Centre for HIV Medicine and Department of Primary Care and Population Sciences, Royal Free and University College, London, UK
    AIDS 15:2385-95. 2001
    ..To assess the factors associated with virologic response to non-nucleoside reverse transcriptase inhibitor (NNRTI)-containing regimens in a large clinic cohort...
  7. ncbi Risk of extensive virological failure to the three original antiretroviral drug classes over long-term follow-up from the start of therapy in patients with HIV infection: an observational cohort study
    Andrew N Phillips
    Department of Primary Care and Population Sciences, Royal Free and University College Medical School, London, UK
    Lancet 370:1923-8. 2007
    ..We estimated the proportion of patients who had extensive triple-class failure during long-term follow-up and examined characteristics associated with an increased rate of failure...
  8. ncbi HIV in the UK 1980-2006: reconstruction using a model of HIV infection and the effect of antiretroviral therapy
    A N Phillips
    Department of Primary Care and Population Sciences, Royal Free Medical School, London, UK
    HIV Med 8:536-46. 2007
    ..We aimed to develop such a model and use it to reconstruct the HIV-infected population in the UK to 2006...
  9. ncbi Rate of AIDS diseases or death in HIV-infected antiretroviral therapy-naive individuals with high CD4 cell count
    Andrew N Phillips
    Department of Primary Care and Population Sciences, Royal Free and University College Medical School, London, UK
    AIDS 21:1717-21. 2007
    ..To assess the absolute rate of AIDS and death in antiretroviral therapy (ART)-naive patients with a high CD4 cell count. Such information would be helpful in the design of a trial investigating early initiation of ART...
  10. ncbi Human immunodeficiency virus rebound after suppression to <400 copies/mL during initial highly active antiretroviral therapy regimens, according to prior nucleoside experience and duration of suppression
    Andrew N Phillips
    Royal Free Centre for HIV Medicine, Royal Free and University College Medical School, Rowland Hill Street, London NW3 2PF, United Kingdom
    J Infect Dis 186:1086-91. 2002
    ..95; P=.009). It appears that only a small period of pre-HAART nucleoside therapy is sufficient to confer a disadvantage, in terms of risk of virus rebound, that persists for several years...
  11. pmc When should antiretroviral therapy for HIV be started?
    Andrew N Phillips
    Department of Primary Care and Population Sciences, Royal Free and University College Medical School, London NW3 2PF
    BMJ 334:76-8. 2007
  12. ncbi Changes in AIDS-defining illnesses in a London Clinic, 1987-1998
    A Mocroft
    Department of Primary Care and Population Sciences, Royal Free Centre for HIV Medicine, Royal Free and University College Medical School, University College London, England
    J Acquir Immune Defic Syndr 21:401-7. 1999
    ....
  13. ncbi Reasons for stopping antiretrovirals used in an initial highly active antiretroviral regimen: increased incidence of stopping due to toxicity or patient/physician choice in patients with hepatitis C coinfection
    A Mocroft
    Royal Free Centre for HIV Medicine and Department of Primary Care and Population Sciences, Royal Free and University College Medical School, London, NW3 2PF UK
    AIDS Res Hum Retroviruses 21:743-52. 2005
    ..Managing adverse events must remain a key intervention in maintaining HAART. There is a need for further studies to describe the relationship between HCV, specific antiretrovirals, and different treatment strategies...
  14. ncbi Time to virological failure of 3 classes of antiretrovirals after initiation of highly active antiretroviral therapy: results from the EuroSIDA study group
    A Mocroft
    Royal Free Centre for HIV Medicine and Department of Primary Care and Population Sciences, Royal Free and University College London Medical Schools, London, United Kingdom
    J Infect Dis 190:1947-56. 2004
    ....
  15. doi Factors associated with viral rebound among highly treatment-experienced HIV-positive patients who have achieved viral suppression
    C J Smith
    Research Department of Infection and Population Health, Royal Free and University College Medical School, London, UK
    HIV Med 10:19-27. 2009
    ..More and more highly treatment-experienced patients are achieving viral suppression. However, the durability of suppression remains unclear...
  16. ncbi Reasons for modification and discontinuation of antiretrovirals: results from a single treatment centre
    A Mocroft
    Department of Primary Care and Populations Sciences, Royal Free Centre for HIV Medicine, Royal Free and University College Medical School, London, UK
    AIDS 15:185-94. 2001
    ..To describe the reasons for, and factors associated with, modification and discontinuation of highly active antiretroviral therapy (HAART) regimens at a single clinic...
  17. doi An audit of viral load in one clinical population to describe features of viraemic patients on antiretroviral therapy
    S Madge
    Royal Free Centre for HIV Medicine, Royal Free and University College London Medical School, London, UK
    HIV Med 9:208-13. 2008
    ..To assess the prevalence of an undetectable viral load (VL) (<50 HIV-1 RNA copies/mL) in a clinical population and to identify those viraemic and at risk of failing antiretroviral therapy (ART)...
  18. ncbi Cytomegalovirus seropositivity and human immunodeficiency virus type 1 RNA levels in individuals with hemophilia
    C A Sabin
    Dept of Primary Care and Population Sciences, Royal Free and University College Medical School, Royal Free Campus, London, United Kingdom NW3 2PF
    J Infect Dis 181:1800-3. 2000
    ..Thus, the effect of CMV seropositivity on clinical progression remains significant in this cohort but does not appear to be mediated through an increase in HIV RNA levels...
  19. ncbi Gender differences in virologic response to treatment in an HIV-positive population: a cohort study
    A L Moore
    Royal Free Centre for HIV Medicine and Department of Primary Care and Population Sciences, Royal Free and University College Medical School, Hampstead, London, United Kingdom
    J Acquir Immune Defic Syndr 26:159-63. 2001
    ..To establish whether a gender difference in virologic response to highly active antiretroviral treatment (HAART) exists...
  20. ncbi Course of viral load throughout HIV-1 infection
    C A Sabin
    Department of Primary Care, Royal Free Centre for HIV Medicine, Royal Free and University College Medical School, London, UK
    J Acquir Immune Defic Syndr 23:172-7. 2000
    ....
  21. ncbi Normalisation of CD4 counts in patients with HIV-1 infection and maximum virological suppression who are taking combination antiretroviral therapy: an observational cohort study
    A Mocroft
    Royal Free and University College Medical School, London, UK
    Lancet 370:407-13. 2007
    ..We aimed to assess whether the CD4 count for patients with maximum virological suppression (viral load <50 copies per mL) continues to increase with long-term cART to reach levels seen in HIV-negative populations...
  22. ncbi The associations between age and the development of laboratory abnormalities and treatment discontinuation for reasons other than virological failure in the first year of highly active antiretroviral therapy
    C A Sabin
    Department of Primary Care and Population Science, Royal Free and UC Medical School, London, UK
    HIV Med 10:35-43. 2009
    ....
  23. ncbi Changing patterns of mortality across Europe in patients infected with HIV-1. EuroSIDA Study Group
    A Mocroft
    Royal Free Centre for HIV Medicine and Department of Primary Care and Population Sciences, Royal Free and University College Medical School, University College London, UK
    Lancet 352:1725-30. 1998
    ..We examined the change in these mortality rates of HIV-1-infected patients across Europe during 1994-98, and assessed the extent to which changes can be explained by the use of new therapeutic regimens...
  24. pmc CD4 counts and the risk of systemic non-Hodgkin's lymphoma in individuals with HIV in the UK
    Mark Bower
    Research Department of Infection and Population Health, Division of Population Health, UCL Medical School, Royal Free Campus, Rowland Hill Street, London, NW3 2PF, UK
    Haematologica 94:875-80. 2009
    ..Earlier highly active anti-retroviral therapy initiation and wider access to HIV testing is advocated to reduce the risk of systemic non-Hodgkin's lymphoma...
  25. ncbi The virological response to highly active antiretroviral therapy over the first 24 weeks of therapy according to the pre-therapy viral load and the weeks 4-8 viral load
    A C Lepri
    Royal Free Centre for HIV Medicine and Department of Primary Care and Population Sciences, Royal Free and University College Medical School, London, UK
    AIDS 15:47-54. 2001
    ..To describe the viral response to HAART by weeks 4 and 8 in previously antiretroviral-naive patients. To assess whether the weeks 4 or 8 viral loads are useful predictors of viral suppression by week 24...
  26. ncbi Patterns and predictors of the use of different antiretroviral drug regimens at treatment initiation in the UK
    P J Easterbrook
    Department of HIV GU Medicine, Kings College London School of Medicine at Guy s, London, UK
    HIV Med 9:47-56. 2008
    ..We describe the patterns of antiretroviral drug use at treatment initiation from 1996 to 2005 in a large UK multicentre cohort...
  27. ncbi Treatment outcomes amongst previously antiretroviral-naïve HIV-infected patients starting lopinavir/ritonavir-containing antiretroviral regimens at the Royal Free Hospital
    C J Smith
    Royal Free Centre for HIV Medicine and Department of Primary Care and Population Sciences, Royal Free and University College Medical School, Rowland Hill Street, London, UK
    HIV Med 8:55-63. 2007
    ..To describe outcomes in patients starting first-line antiretroviral regimens including lopinavir/ritonavir (LPV/r) in a routine clinic setting...
  28. doi Use of a prescription-based measure of antiretroviral therapy adherence to predict viral rebound in HIV-infected individuals with viral suppression
    V Cambiano
    HIV Epidemiology and Biostatistics Group, Research Department of Infection and Population Health, UCL Medical School, London, UK
    HIV Med 11:216-24. 2010
    ..The aim of the study was to assess whether a simple, routinely available measure of antiretroviral therapy (ART) adherence predicts viral rebound at the next HIV viral load (VL) measurement in virally suppressed patients...
  29. pmc Antiretroviral therapy CNS penetration and HIV-1-associated CNS disease
    L Garvey
    Imperial College, Norfolk Place, London, UK
    Neurology 76:693-700. 2011
    ....
  30. ncbi Durability of HIV-1 viral suppression over 3.3 years with multi-drug antiretroviral therapy in previously drug-naive individuals
    A N Phillips
    Royal Free Centre for HIV Medicine and Department of Primary Care and Population Sciences, Royal Free and University College Medical School, London, UK
    AIDS 15:2379-84. 2001
    ..The major challenge is to develop regimens that can be taken consistently and safely for such long periods of time...
  31. ncbi Haemoglobin and albumin as markers of HIV disease progression in the highly active antiretroviral therapy era: relationships with gender
    S Shah
    Department of Thoracic Medicine, Royal Free Centre for HIV Medicine, Royal Free and University College Medical School and Royal Free Hospital, Rowland Hill Street, London, UK
    HIV Med 8:38-45. 2007
    ..The aims of the study were to describe gender differences in haemoglobin and albumin and to investigate the prognostic value of these measurements in relation to highly active antiretroviral therapy (HAART)...
  32. ncbi Reasons for stopping antiretrovirals used in an initial highly active antiretroviral regimen: increased incidence of stopping due to toxicity or patient/physician choice in patients with hepatitis C coinfection
    A Mocroft
    Royal Free Centre for HIV Medicine and Department of Primary Care and Population Sciences, Royal Free and University College London Medical Schools, Roayal Free campus, London, UK
    AIDS Res Hum Retroviruses 21:527-36. 2005
    ..Managing adverse events must remain a key intervention in maintaining HAART. There is a need for further studies to describe the relationship between HCV, specific antiretrovirals, and different treatment strategies...
  33. doi Evaluating the extent of potential resistance to pre-exposure prophylaxis within the UK HIV-1-infectious population of men who have sex with men
    D Dölling
    HIV and Infections Group, MRC Clinical Trials Unit, London, UK
    HIV Med 13:309-14. 2012
    ..Our objective was to evaluate the likelihood that a UK man who has sex with men (MSM) would be exposed to PrEP-resistant HIV in a homosexual encounter with an HIV-infectious partner...
  34. doi The rate of accumulation of nonnucleoside reverse transcriptase inhibitor (NNRTI) resistance in patients kept on a virologically failing regimen containing an NNRTI*
    A Cozzi-Lepri
    Department of Infection and Population Health, Division of Population Health, University College London, London, UK
    HIV Med 13:62-72. 2012
    ..How quickly NNRTI resistance accumulates in patients with a delayed switch from nevirapine or efavirenz despite virological failure, when these drugs are used as a component of combination antiretroviral therapy (cART), remains unclear...
  35. doi Long-term trends in CD4 cell counts and impact of viral failure in individuals starting antiretroviral therapy: UK Collaborative HIV Cohort (CHIC) study
    R A Hughes
    University of Bristol, School of Social and Community Medicine, Bristol, UK St Mary s NHS Trust, London, UK
    HIV Med 12:583-93. 2011
    ....
  36. ncbi The feasibility of clinical endpoint trials in HIV infection in the highly active antiretroviral treatment (HAART) era
    A Mocroft
    Royal Free Centre for HIV Medicine, Dept Primary Care and Population Sciences, Royal Free and University College Medical School, Royal Free Campus, Rowland Hill St, London NW3 2PF, UK
    Clin Trials 3:119-32. 2006
    ..Cohort studies of patients with HIV can provide key estimates of the likely disease progression, required sample size and follow-up...
  37. ncbi Relationships among the detection of p24 antigen, human immunodeficiency virus (HIV) RNA level, CD4 cell count, and disease progression in HIV-infected individuals with hemophilia
    C A Sabin
    Department of Primary Care and Population Sciences, Royal Free Centre for HIV Medicine, Royal Free and University College Medical School, Rowland Hill St, London NW3 2PF, United Kingdom
    J Infect Dis 184:511-4. 2001
    ..85; P=.06) after adjusting for CD4 cell counts and HIV RNA levels during follow-up, age, and calendar year. A significant relationship between p24 antigenemia and death was nonsignificant after adjusting for CD4 cell count...
  38. ncbi Decline in the AIDS and death rates in the EuroSIDA study: an observational study
    A Mocroft
    Royal Free Centre for HIV Medicine and Department of Primary Care and Population Sciences, Royal Free and University College Medical School, London, UK
    Lancet 362:22-9. 2003
    ..Since the introduction of highly active antiretroviral therapy (HAART), little is known about whether changes in HIV-1 mortality and morbidity rates have been sustained. We aimed to assess possible changes in these rates across Europe...
  39. ncbi Are there gender differences in starting protease inhibitors, HAART, and disease progression despite equal access to care?
    A Mocroft
    Royal Free Centre for HIV Medicine, Departments of Primary Care and Population Sciences, Royal Free and University College Medical School, London, UK
    J Acquir Immune Defic Syndr 24:475-82. 2000
    ....
  40. pmc Changes over time in risk factors for cardiovascular disease and use of lipid-lowering drugs in HIV-infected individuals and impact on myocardial infarction
    C A Sabin
    Dept of Primary Care and Population Sciences, Royal Free and UC Medical School, Rowland Hill St, London, NW3 2PF, United Kingdom
    Clin Infect Dis 46:1101-10. 2008
    ..We evaluated changes in risk factors for CVD and the use of lipid-lowering therapy in HIV-infected individuals and assessed the impact of any changes on the incidence of myocardial infarction...
  41. ncbi Changes in lymphocyte subsets in human immunodeficiency virus-positive persons with < 5 CD4 T lymphocytes/mm3
    C A Sabin
    Department of Primary Care and Population Sciences, Royal Free Hospital and School of Medicine, London, United Kingdom
    J Infect Dis 178:1166-9. 1998
    ..Despite almost a complete absence of CD4 T lymphocytes, lymphocyte subset monitoring is useful in identifying decreasing CD8 T lymphocyte levels that predict short-term prognosis...
  42. pmc Interruption of antiretroviral therapy is associated with increased plasma cystatin C
    Amanda Mocroft
    University College London Medical School, London, UK
    AIDS 23:71-82. 2009
    ....
  43. ncbi Use of a stochastic model to develop understanding of the impact of different patterns of antiretroviral drug use on resistance development
    A N Phillips
    Royal Free Centre for HIV Medicine, Royal Free and University College Medical School, University College London, London, UK
    AIDS 15:2211-20. 2001
    ..CONCLUSIONS: This model helps to develop understanding of key principles concerning development of resistance under different patterns of treatment use...
  44. ncbi The practical significance of potential biases in estimates of the AIDS incubation period distribution in the UK register of HIV seroconverters
    K Porter
    Medical Research Council Clinical Trials Unit, London, UK
    AIDS 13:1943-51. 1999
    ....
  45. ncbi Reduced bone mineral density in HIV-positive individuals
    A L Moore
    Centre for HIV Medicine, Royal Free Hospital, London, UK
    AIDS 15:1731-3. 2001
    ..Our results suggest a possible association between PI and reduced BMD, and further complicate the debate regarding when to commence treatment of HIV and with what agents to start...
  46. ncbi An audit of antiretroviral treatment use in HIV-infected patients in a London clinic: the limitations of observational databases when auditing antiretroviral treatment use
    C A Sabin
    Royal Free Centre for HIV Medicine, Department of Primary Care and Population Sciences, Royal Free and University College Medical School, Rowland Hill Street, London, UK
    HIV Med 4:87-93. 2003
    ..To audit the use of antiretroviral (ARV) treatment in a large treatment clinic in the UK against the British HIV Association (BHIVA) ARV treatment guidelines...
  47. ncbi When to start highly active antiretroviral therapy in chronically HIV-infected patients: evidence from the ICONA study
    A Cozzi Lepri
    Royal Free Centre for HIV Medicine and Department of Primary Care and Population Sciences, Royal Free and University College Medical School, Royal Free Campus, London, UK
    AIDS 15:983-90. 2001
    ..The increase in CD4 cells restored by HAART is meaningful in that they are associated with reduced risk of disease/death...
  48. ncbi Response to antiretroviral therapy among patients exposed to three classes of antiretrovirals: results from the EuroSIDA study
    A Mocroft
    Royal Free Centre for HIV Medicine, Department of Primary Care and Population Sciences, Royal Free and University College Medical School, London, UK
    Antivir Ther 7:21-30. 2002
    ..Outcomes in people starting salvage regimens appear to depend on the number of new drugs started but not on the total number of drugs being used...
  49. pmc A survey of ATRIPLA use in clinical practice as first-line therapy in HIV-positive persons in Europe
    A Mocroft
    Department of Infection and Population Health, University College London, Rowland Hill St, London, NW3 2PF, UK
    Infection 42:757-62. 2014
    ..4 %), and least common in Eastern Europe (2/31 clinics; 6.5 %; p < 0.0001). Over one-third of the participating clinics in this survey were using ATRIPLA as first-line antiretroviral therapy, despite EMA recommendations. ..
  50. ncbi British HIV Association (BHIVA) guidelines for the treatment of HIV-infected adults with antiretroviral therapy
    A Pozniak
    Chelsea and Westminster Hospital, London, UK
    HIV Med 4:1-41. 2003
  51. ncbi Antiretroviral therapy for prevention of HIV transmission: implications for Europe
    V Cambiano
    Research Department of Infection and Population Health, Institute of Epidemiology and Health Care, University College London, London, United Kingdom
    Euro Surveill 18:20647. 2013
    ..Other proven prevention means such as condom use and harm reduction for people who inject drugs remain critical...
  52. ncbi Risk factors for tuberculosis in patients with AIDS in London: a case-control study
    J del Amo
    MRC UK Centre for Co ordinating Epidemiological Studies of HIV and AIDS, Department of STD, Mortimer Market Centre, London, UK
    Int J Tuberc Lung Dis 3:12-7. 1999
    ..To identify risk factors for the acquired immune-deficiency syndrome (AIDS) associated with tuberculosis, in patients with AIDS attending 11 of the largest human immunodeficiency virus (HIV)/AIDS Units in London...
  53. pmc Activation and coagulation biomarkers are independent predictors of the development of opportunistic disease in patients with HIV infection
    Alison J Rodger
    HIV Epidemiology and Biostatistics Group, Research Dept of Infection and Population Health, UCL Medical School, University College London, London, UK
    J Infect Dis 200:973-83. 2009
    ..Their associations with opportunistic disease (OD) in human immunodeficiency virus (HIV)-positive patients were examined...
  54. pmc Viral resuppression and detection of drug resistance following interruption of a suppressive non-nucleoside reverse transcriptase inhibitor-based regimen
    Zoe Fox
    Copenhagen HIV Programme, University of Copenhagen Rigshospitalet, Copenhagen, Denmark
    AIDS 22:2279-89. 2008
    ..Limited data exist to guide clinical practice on the best interruption strategy to use...
  55. doi Loss to follow-up in an international, multicentre observational study
    A Mocroft
    Royal Free and University College Medical School, London, UK
    HIV Med 9:261-9. 2008
    ..The aim of this work was to assess loss to follow-up (LTFU) in EuroSIDA, an international multicentre observational cohort study...
  56. doi History of viral suppression on combination antiretroviral therapy as a predictor of virological failure after a treatment change
    J Reekie
    Research Department of Infection and Population Health, University College London Medical School, UK
    HIV Med 11:469-78. 2010
    ..The relationship between such differences and risk of virological failure after starting a new antiretroviral could help with patient monitoring strategies...
  57. ncbi Trends over calendar time in antiretroviral treatment success and failure in HIV clinic populations
    L Bansi
    UCL Medical School, Royal Free Campus, London, UK
    HIV Med 11:432-8. 2010
    ..Effective antiretroviral therapy (ART) has transformed the care of people with HIV, but it is important to monitor time trends in indicators of treatment success and antic future changes...
  58. pmc Death rates in HIV-positive antiretroviral-naive patients with CD4 count greater than 350 cells per microL in Europe and North America: a pooled cohort observational study
    Rebecca K Lodwick
    HIV Epidemiology and Biostatistics Group, Research Department of Infection and Population Health, UCL Medical School, Royal Free Campus, London, UK
    Lancet 376:340-5. 2010
    ..We aimed to examine this by analysis of pooled data from industrialised countries...
  59. doi Relationship between current level of immunodeficiency and non-acquired immunodeficiency syndrome-defining malignancies
    Joanne Reekie
    University College London Medical School, London, UK
    Cancer 116:5306-15. 2010
    ..However, conflicting data have been reported on the relationship between immunodeficiency and the development of some non-AIDS-defining malignancies...
  60. ncbi The prevalence of hepatitis C virus (HCV) infection in HIV-positive individuals in the UK - trends in HCV testing and the impact of HCV on HIV treatment outcomes
    J Turner
    Centre for Sexual Health and HIV Research, UCL Medical School and The Mortimer Market Centre, Camden Primary Care Trust, London, UK
    J Viral Hepat 17:569-77. 2010
    ..HCV infection had no impact on HIV virological outcomes or immunological response to HIV treatment. The long-term impact on morbidity and mortality remain to be determined...
  61. doi Serious fatal and nonfatal non-AIDS-defining illnesses in Europe
    Amanda Mocroft
    Research Department of Infection and Population Health, University College Medical School, London, UK
    J Acquir Immune Defic Syndr 55:262-70. 2010
    ..Little is known about the incidence and risk factors for serious non-AIDS-defining events...
  62. doi Does less frequent routine monitoring of patients on a stable, fully suppressed cART regimen lead to an increased risk of treatment failure?
    Joanne Reekie
    HIV Epidemiology and Biostatistics Group, Research Department of Infection and Population Health, Royal Free and University College Medical School, London, UK
    AIDS 22:2381-90. 2008
    ..To investigate whether HIV-infected patients on a stable and fully suppressive combination antiretroviral therapy (cART) regimen could safely be monitored less often than the current recommendations of every 3 months...
  63. doi Detection of HIV drug resistance during antiretroviral treatment and clinical progression in a large European cohort study
    Alessandro Cozzi-Lepri
    Research Department of Infection and Population Health, Royal Free and University College Medical School, London, UK
    AIDS 22:2187-98. 2008
    ..To investigate the relationship between detection of HIV drug resistance by 2 years from starting antiretroviral therapy and the subsequent risk of progression to AIDS and death...
  64. doi Transmitted drug resistant HIV-1 and association with virologic and CD4 cell count response to combination antiretroviral therapy in the EuroSIDA Study
    Wendy P Bannister
    Department of Primary Care and Population Sciences, Royal Free and University College Medical School, London, United Kingdom
    J Acquir Immune Defic Syndr 48:324-33. 2008
    ..To investigate prevalence of transmitted drug-resistant human immunodeficiency virus (TDR) and factors associated with TDR and to compare virological and CD4 count response to combination antiretroviral therapy...
  65. doi Estimated glomerular filtration rate, chronic kidney disease and antiretroviral drug use in HIV-positive patients
    Amanda Mocroft
    HIV Epidemiology and Biostatistics Group, Research Department of Infection and Population Health, Division of Population Health, University College London Medical School, Royal Free Campus, London, UK
    AIDS 24:1667-78. 2010
    ..Chronic kidney disease (CKD) in HIV-positive persons might be caused by both HIV and traditional or non-HIV-related factors. Our objective was to investigate long-term exposure to specific antiretroviral drugs and CKD...
  66. ncbi Rate of accumulation of thymidine analogue mutations in patients continuing to receive virologically failing regimens containing zidovudine or stavudine: implications for antiretroviral therapy programs in resource-limited settings
    Alessandro Cozzi-Lepri
    Research Department of Infection and Population Health, Royal Free and University College Medical School, London, United Kingdom
    J Infect Dis 200:687-97. 2009
    ....
  67. pmc Refocusing health promotion for syphilis prevention: results of a case-control study of men who have sex with men on England's south coast
    J Imrie
    HIV GUM Research Department, Brighton General Hospital, Elm Grove, UK
    Sex Transm Infect 82:80-3. 2006
    ..Detailed studies of the determinants of syphilis transmission are needed to inform new prevention interventions...
  68. ncbi The changing demographics of new HIV diagnoses at a London centre from 1994 to 2000
    S M Barry
    Department of Thoracic and HIV Medicine, Royal Free Centre for HIV Medicine, London, UK
    HIV Med 3:129-34. 2002
    ..To document the demographic changes in new HIV diagnoses at the Royal Free Hospital, London, UK, between 1994 and 2000...
  69. doi How does HIV impact on non-AIDS events in the era of HAART?
    T J Barber
    Camden Primary Care Trust, Mortimer Market Centre, London, UK
    Int J STD AIDS 20:1-3. 2009
    ..We review these data, as well as discussing some of the possible effects HAART might have on non-AIDS diagnoses and deaths in HIV-positive individuals with successfully treated HIV...
  70. ncbi What is the risk of mortality following diagnosis of multidrug-resistant HIV-1?
    D Grover
    Centre of Sexual Health and HIV Research, Department of Primary Care and Population Sciences, Mortimer Market Centre, London, UK
    J Antimicrob Chemother 61:705-13. 2008
    ..Changing antiretroviral therapy following emergence of MDR HIV-1 may be associated with improved short-term virological response...
  71. pmc Human immunodeficiency virus (HIV) antibody avidity testing to identify recent infection in newly diagnosed HIV type 1 (HIV-1)-seropositive persons infected with diverse HIV-1 subtypes
    A Chawla
    Department of Virology, Royal Free Hospital, Royal Free and University College Medical School, London, UK
    J Clin Microbiol 45:415-20. 2007
    ..Results are affected by advanced disease and should therefore be interpreted in the context of other clinical parameters...
  72. ncbi When should antiretroviral therapy be started for HIV infection? Interpreting the evidence from observational studies
    Andrew N Phillips
    AIDS 17:1863-9. 2003
  73. ncbi Rate of viral rebound according to specific drugs in the regimen in 2120 patients with HIV suppression
    Andrew N Phillips
    Royal Free Centre for HIV Medicine, Department of Primary Care and Population Sciences, Royal Free and University College Medical School, London, UK
    AIDS 18:1795-804. 2004
    ..It is currently unclear whether the tendency for viral rebound in patients with viral load < 50 copies/ml differs according to the specific drug regimen being used...
  74. ncbi Combination antiretroviral therapy and the risk of myocardial infarction
    Nina Friis-Møller
    N Engl J Med 349:1993-2003. 2003
    ..It remains controversial whether exposure to combination antiretroviral treatment increases the risk of myocardial infarction...
  75. pmc Indirect comparisons: a novel approach to assessing the effect of anti-HIV drugs
    Jens D Lundgren
    Copenhagen HIV Programme, Section 044, Hvidovre University Hospital, 2650 Hvidovre, Denmark
    BMJ 328:253. 2004
  76. ncbi Drug switching and virologic-based endpoints in trials of antiretroviral drugs for HIV infection
    Andrew N Phillips
    AIDS 18:365-70. 2004
  77. ncbi The changing pattern of Kaposi sarcoma in patients with HIV, 1994-2003: the EuroSIDA Study
    Amanda Mocroft
    Royal Free Centre for HIV Medicine, Royal Free and University College Medical School, London, United Kingdom
    Cancer 100:2644-54. 2004
    ....
  78. ncbi Predictors of trend in CD4-positive T-cell count and mortality among HIV-1-infected individuals with virological failure to all three antiretroviral-drug classes
    Bruno Ledergerber
    Division of Infectious Diseases and Hospital Epidemiology, University Hospital Zurich, Ramistrasse 100, CH 8091 Zurich, Switzerland
    Lancet 364:51-62. 2004
    ..We aimed to assess the inter-relations between viral load, CD4-cell count, and clinical outcome in patients who had experienced three-class virological failure...
  79. ncbi Use of viral load measured after 4 weeks of highly active antiretroviral therapy to predict virologic outcome at 24 weeks for HIV-1-positive individuals
    Colette J Smith
    Royal Free Centre for HIV Medicine and Department of Primary Care and Population Sciences, Royal Free and University College Medical School, Royal Free Campus, London, United Kingdom
    J Acquir Immune Defic Syndr 37:1155-9. 2004
    ..We suggest that this group of patients should be particularly closely monitored...
  80. ncbi Baseline resistance and virological outcome in patients with virological failure who start a regimen containing abacavir: EuroSIDA study
    Cecilia Cabrera
    IrsiCaixa Foundation and Lluita contra la SIDA Foundation, Badalona, Spain
    Antivir Ther 9:787-800. 2004
    ....
  81. ncbi Virological rebound after suppression on highly active antiretroviral therapy
    Amanda Mocroft
    Royal Free Centre for HIV Medicine and Department of Primary Care and Population Sciences, Royal Free and University College Medical School, London, UK
    AIDS 17:1741-51. 2003
    ..Treatment-naive patients were at a lower risk of rebound, but among drug-experienced patients, those who added new nucleosides had a lower risk of rebound, as were patients with a good immunological response...
  82. ncbi Cardiovascular disease risk factors in HIV patients--association with antiretroviral therapy. Results from the DAD study
    Nina Friis-Møller
    DAD Coordinating Centre, Copenhagen HIV Programme, Hvidovre University Hospital, Copenhagen, Denmark
    AIDS 17:1179-93. 2003
    ..To determine the prevalence of risk factors for cardiovascular disease (CVD) among HIV-infected persons, and to investigate any association between such risk factors, stage of HIV disease, and use of antiretroviral therapies...
  83. ncbi Virological suppression at 6 months is related to choice of initial regimen in antiretroviral-naive patients: a cohort study
    Gail V Matthews
    Department of HIV Medicine, Chelsea Hospital, London, UK
    AIDS 16:53-61. 2002
    ....
  84. ncbi Brief report: two-year outcome of a multidrug regimen in patients who did not respond to a protease inhibitor regimen
    Mike Youle
    Royal Free Centre for HIV Medicine, Royal Free and University College Medical School, London, United Kingdom
    J Acquir Immune Defic Syndr 29:58-61. 2002
    ..Thus, a substantial proportion of patients who had failed to respond virologically to PI-containing regimens can achieve profound and sustained virologic suppression with a multidrug regimen...
  85. ncbi Raised viral load in patients with viral suppression on highly active antiretroviral therapy: transient increase or treatment failure?
    Antonia L Moore
    Department of Primary Care and Population Sciences and Centre for HIV Medicine, Royal Free and University College School of Medicine, Hampstead, London NW3 2PF, UK
    AIDS 16:615-8. 2002
    ....
  86. ncbi Virologic and immunologic response to regimens containing nevirapine or efavirenz in combination with 2 nucleoside analogues in the Italian Cohort Naive Antiretrovirals (I.Co.N.A.) study
    Alessandro Cozzi-Lepri
    Royal Free Centre for HIV Medicine, Department of Primary Care and Population Sciences, Royal Free and University College Medical School, Rowland Hill Street, London NW3 2PF, UK
    J Infect Dis 185:1062-9. 2002
    ..The findings of this study are in agreement with those of other observational studies...
  87. ncbi CD4 cell count changes in individuals with counts above 500 cells/mm and viral loads below 50 copies/ml on antiretroviral therapy
    Andrew N Phillips
    Royal Free Centre for HIV Medicine, London, UK
    AIDS 16:1073-5. 2002
  88. ncbi Prognosis of HIV-1-infected patients starting highly active antiretroviral therapy: a collaborative analysis of prospective studies
    Matthias Egger
    Department of Social and Preventive Medicine, University of Bern, CH 3012 Bern, Switzerland
    Lancet 360:119-29. 2002
    ..The ART Cohort Collaboration, which includes 13 cohort studies from Europe and North America, was established to fill this knowledge gap...
  89. ncbi Association of virus load, CD4 cell count, and treatment with clinical progression in human immunodeficiency virus-infected patients with very low CD4 cell counts
    Veronica Miller
    Klinikum der Johann Wolfgang Goethe Universitat, Zentrum der Inneren Medizin, Frankfurt, Germany
    J Infect Dis 186:189-97. 2002
    ..10, P<.0001, respectively, for 4, 3, 2, 1, or no drugs vs. >or=5 drugs). Although reverse causality cannot be excluded, more intense antiviral treatment appears to decrease the risk of progression in immunocompromised patients...
  90. ncbi Intermittent and sustained low-level HIV viral rebound in patients receiving potent antiretroviral therapy
    Gilbert Greub
    University Hospital, Lausanne, Switzerland
    AIDS 16:1967-9. 2002
  91. ncbi Changes over calendar time in the risk of specific first AIDS-defining events following HIV seroconversion, adjusting for competing risks
    Abdel Babiker
    Int J Epidemiol 31:951-8. 2002
    ..We wished to evaluate changes over time in the risk of specific AIDS-defining diseases, as first events, using data from individuals with known dates of HIV seroconversion...
  92. ncbi Virologic, immunologic, and clinical response to highly active antiretroviral therapy: the gender issue revisited
    Antonia L Moore
    Department of Primary Care and Population Sciences, Royal free and University College School fo Medicine, Hampstead, London, UK
    J Acquir Immune Defic Syndr 32:452-61. 2003
    ..Highly active antiretroviral therapy (HAART) has dramatically improved the prognosis for patients with HIV. There is ongoing debate over a potential gender effect on patient outcome after HAART...
  93. ncbi The potential for CD4 cell increases in HIV-positive individuals who control viraemia with highly active antiretroviral therapy
    Colette J Smith
    Royal Free Centre for HIV Medicine and Department of Primary Care and Population Sciences, Royal Free and University College Medical School, Royal Free Campus, London, UK
    AIDS 17:963-9. 2003
    ..To study the long-term CD4 cell responses to highly active antiretroviral therapy (HAART) in treatment-naive patients whose viral loads remained below 500 copies/ml for prolonged periods...
  94. ncbi Changes in viral load in people with virological failure who remain on the same HAART regimen
    Alessandro Cozzi-Lepri
    Royal Free Centre for HIV Medicine and Department of Primary Care and Population Sciences, Royal Free and University College Medical School, Royal Free Campus, London, UK
    Antivir Ther 8:127-36. 2003
    ..To assess the rate of change in viral load and CD4 count over time in HIV-infected patients experiencing virological failure on a HAART regimen...
  95. ncbi Inferior clinical outcome of the CD4+ cell count-guided antiretroviral treatment interruption strategy in the SMART study: role of CD4+ Cell counts and HIV RNA levels during follow-up
    Jens D Lundgren
    Copenhagen HIV Programme CHIP, Faculty of Health Sciences, University of Copenhagen, Panum Institute, 2200 Copenhagen N, Denmark
    J Infect Dis 197:1145-55. 2008
    ..Rates and predictors of opportunistic disease or death (OD/death) and the relative risk (RR) in DC versus VS groups according to the latest CD4+ cell count and HIV RNA level are reported...
  96. ncbi Major clinical outcomes in antiretroviral therapy (ART)-naive participants and in those not receiving ART at baseline in the SMART study
    Sean Emery
    Therapeutic and Vaccine Research Program, National Centre in HIV Epidemiology and Clinical Research, University of New South Wales, 376 Victoria St, Sydney, NSW 2010, Australia
    J Infect Dis 197:1133-44. 2008
    ..In the DC group, participants started ART when the CD4+ cell count was <250 cells/microL. Clinical outcomes in participants not receiving ART at entry inform the early use of ART...
  97. ncbi Causes of death in HIV infection: the key determinant to define the clinical response to anti-HIV therapy
    Amanda Mocroft
    Royal Free Centre for HIV Medicine and Department of Primary Care and Population Sciences, Royal Free and University College Medical School, London, UK
    AIDS 18:2333-7. 2004
    ..Compared with homosexual individuals, IDU had an increased incidence of new AIDS/death, but only for non-HIV deaths. There is an urgent need to define and standardize causes of death in observational studies...
  98. ncbi Increased duration of viral suppression is associated with lower viral rebound rates in patients with previous treatment failures
    Andrew A Benzie
    St Mary s Hospital, London, UK
    AIDS 21:1423-30. 2007
    ....
  99. ncbi Effect of transient antiretroviral treatment during acute HIV infection: comparison of the Quest trial results with CASCADE natural history study
    Fiona C Lampe
    Royal Free Centre for HIV Medicine, Royal Free and University College Medical School, London, UK
    Antivir Ther 12:189-93. 2007
    ..6 years, and 17.7% (95% confidence interval [CI]: 10.9-27.6) fulfilled the primary endpoint of VL < or =1,000 copies/ml 24 weeks after CART discontinuation...
  100. ncbi Evolution of drug resistance in HIV-infected patients remaining on a virologically failing combination antiretroviral therapy regimen
    Alessandro Cozzi-Lepri
    Royal Free and University College Medical School, London, UK
    AIDS 21:721-32. 2007
    ..To estimate the extent of drug resistance accumulation in patients kept on a virologically failing regimen and its determinants in the clinical setting...
  101. ncbi Predictors of CD4 count change over 8 months of follow up in HIV-1-infected patients with a CD4 count>or=300 cells/microL who were assigned to 7.5 MIU interleukin-2
    Zoe Fox
    Hvidovre University Hospital, DK 2650 Hvidovre, Denmark
    HIV Med 8:112-23. 2007
    ..The IL-2 induction phase consists of three dosing cycles over 6-8 months (7.5 MIU twice a day, for 5 days every 8 weeks)...